Latest News

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

The quarterly results for The Supreme Industries Limited ( NSE:SUPREMEIND ) were released last week, making it a good...

With a price-to-earnings (or "P/E") ratio of 12.6x Arrow Greentech Limited ( NSE:ARROWGREEN ) may be sending bullish...

Investing in stocks inevitably means buying into some companies that perform poorly. But long term Andhra Cements...

Last week, you might have seen that Sagar Cements Limited ( NSE:SAGCEM ) released its quarterly result to the market...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...

It's been a sad week for Rajratan Global Wire Limited ( NSE:RAJRATAN ), who've watched their investment drop 13% to...

Even the best stock pickers will make plenty of bad investments. And unfortunately for SEPC Limited ( NSE:SEPC...

Some Cosmo First Limited ( NSE:COSMOFIRST ) shareholders are probably rather concerned to see the share price fall 33...

The Wanbury Limited ( NSE:WANBURY ) share price has fared very poorly over the last month, falling by a substantial...

It is hard to get excited after looking at Coforge's (NSE:COFORGE) recent performance, when its stock has declined 7.0...

Burke & Herbert Financial Services (BHRB) has capped FY 2025 with fourth quarter revenue of US$86.4 million and EPS of US$2.00, against a trailing twelve month tally of US$340.5 million in revenue and EPS of US$7.72. The company has seen revenue move from US$233.0 million and EPS of about US$2.83 on a trailing basis a year earlier to US$340.5 million and EPS of US$7.72, which helps explain why trailing net income is now US$116.4 million. With net margin reported at 34.2% for the latest twelve...

Alamos Gold (TSX:AGI) is back in focus after new surface drilling results in Mexico extended high grade gold mineralization at Puerto Del Aire and Cerro Pelon, along with a fresh sulphide discovery at the Halcon target. See our latest analysis for Alamos Gold. The recent exploration updates arrive alongside strong share price momentum, with a 34.75% 90 day share price return and a very large 5 year total shareholder return. This suggests investors are increasingly pricing in both growth...

Capital moves at TD: buybacks and debt redemption The Toronto-Dominion Bank (TSX:TD) has put capital management in focus, pairing a new share repurchase program with ongoing buybacks and a planned redemption of subordinated notes that affects its funding mix. See our latest analysis for Toronto-Dominion Bank. TD’s capital moves come as the share price sits at CA$130.37, with a 90 day share price return of 15.02%, while the 1 year total shareholder return of 65.36% points to strong recent...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Madison Square Garden Entertainment Corp. has announced that international superstar Harry Styles will headline 30 consecutive shows at Madison Square Garden from August through October 2026, forming his only US dates that year and the largest single-venue stop on his Together, Together world tour. This residency, combined with MSGE’s record-breaking 2025 Christmas Spectacular attendance, advanced venue technology, and plans for new Sphere locations, highlights how the company is...

United Spirits Limited ( NSE:UNITDSPR ) stock is about to trade ex-dividend in 2 days. The ex-dividend date is commonly...

Recent commentary on Intellia Therapeutics (NTLA) is focused on safety concerns and regulatory pauses in its transthyretin amyloidosis program, as well as questions about commercial potential for its hereditary angioedema therapy. See our latest analysis for Intellia Therapeutics. Intellia's recent safety headlines come on top of sharp price swings. The company recorded a 1 day share price return of negative 7.99% following a 30 day share price return of 52.55%. Its 1 year total shareholder...

Earlier this week, Array Technologies was swept up in a broad market rally after the US President announced a framework for a future deal with Greenland that eased global trade tensions and lifted sentiment toward renewable energy and infrastructure names. The episode underlines how Array’s investment story can be heavily influenced by shifts in geopolitical risk and market appetite for renewables-linked assets rather than company-specific developments alone. Next, we’ll examine how this...

Medical Properties Trust (MPW) is back in focus as investors react to rising optimism around its upcoming earnings, with upward estimate revisions and heavy call option activity drawing fresh attention to the hospital focused REIT. See our latest analysis for Medical Properties Trust. At a share price of $5.11, Medical Properties Trust has seen mixed recent momentum, with a 1 year total shareholder return of 16.33% set against a 3 year total shareholder return decline of 48.25% and a 5 year...

Inspire Medical Systems recently appointed Matt Osberg as Executive Vice President and Chief Financial Officer, while also issuing updated revenue guidance for the fourth quarter of 2025, full-year 2025, and full-year 2026. These developments coincided with new uncertainty around Medicare reimbursement after two regional contractors removed a key billing code for the company’s hypoglossal nerve stimulation therapy, raising questions about how payment policies could interact with Inspire’s...

In recent days, Cheniere Energy has seen short interest fall markedly while multiple research firms have upgraded their views on the liquefied natural gas exporter, citing supportive demand and project progress. This combination of easing bearish positioning and more favorable analyst commentary signals a meaningful shift in how market participants assess the company’s risk-reward profile. Next, we’ll examine how the sharp reduction in short interest influences Cheniere Energy’s investment...

Container Corporation of India Limited's ( NSE:CONCOR ) price-to-earnings (or "P/E") ratio of 27.9x might make it look...

Earlier this week, Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for treatment with BRAFTOVI (encorafenib) plus cetuximab and chemotherapy. This marks the test’s first approval in colorectal cancer and its 25th companion diagnostic indication overall, underscoring the expanding role of non-invasive genomic profiling in tailoring treatment when tissue samples...